Description: Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Home Page: www.bicara.com
116 Huntington Avenue
Boston,
MA
02116
United States
Phone:
617 468 4219
Officers
| Name | Title |
|---|---|
| Ms. Claire Mazumdar Clemon M.B.A., Ph.D. | CEO & Director |
| Mr. Ryan Cohlhepp Pharm.D. | President, COO & Director |
| Mr. Ivan Hyep M.B.A. | Chief Financial Officer |
| Ms. Lara S. Meisner J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Rachel Salazar | SVP of R&D Strategy and Operations |
| Ms. Sathish Hasige Ph.D. | Senior VP and Head of Technical Operations & Supply Chain |
| Dr. David Raben M.D. | Chief Medical Officer |
| Ms. Angela Windt | VP & Head of Regulatory Affairs |
| Dr. Jeltje Schulten M.B.A., M.D. | Senior Vice President of Clinical & Medical Affairs |
| Mr. Jean-Paul Rodrique | Senior VP & Global Head of Quality Assurance |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.154 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-09-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |